(CANCER) Personalised Postoperative Immunotherapy To Improving Cancer Outcome and improving quality of life
During this RISE project we aim to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective treatment however, have several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state.
Our proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions.
On implementing the new techniques it will lead us to a lifetime of protection against cancer.
More detailed information
Prof. dr. Clemens Löwik
Role Erasmus MC: